A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Serelaxin (Primary)
  • Indications Acute heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms Relax-AHF-2
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 Trial design published in the European Journal of Heart Failure
    • 22 Mar 2017 Primary endpoint has not been met. (Time to confirmed cardiovascular (CV) death during the follow-up period of 180 days), according to a Novartis media release.
    • 02 Mar 2017 This trial has been completed in Portugal as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top